CO2021017433A2 - Agonistas del receptor del péptido-1 similar al glucagón - Google Patents

Agonistas del receptor del péptido-1 similar al glucagón

Info

Publication number
CO2021017433A2
CO2021017433A2 CONC2021/0017433A CO2021017433A CO2021017433A2 CO 2021017433 A2 CO2021017433 A2 CO 2021017433A2 CO 2021017433 A CO2021017433 A CO 2021017433A CO 2021017433 A2 CO2021017433 A2 CO 2021017433A2
Authority
CO
Colombia
Prior art keywords
glucagon
peptide
receptor agonists
compound
formula
Prior art date
Application number
CONC2021/0017433A
Other languages
English (en)
Inventor
David Andrew Coates
Todd Fields
Joseph Daniel Ho
Fucheng Qu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2021017433A2 publication Critical patent/CO2021017433A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

En una modalidad, la presente invención proporciona un compuesto de la fórmula: o una sal farmacéuticamente aceptable del mismo, y métodos para usar este compuesto en el tratamiento de la diabetes mellitus tipo II.
CONC2021/0017433A 2019-06-28 2021-12-20 Agonistas del receptor del péptido-1 similar al glucagón CO2021017433A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868117P 2019-06-28 2019-06-28
US201962904906P 2019-09-24 2019-09-24
PCT/US2020/038617 WO2020263695A1 (en) 2019-06-28 2020-06-19 Glucagon-like peptide 1 receptor agonists

Publications (1)

Publication Number Publication Date
CO2021017433A2 true CO2021017433A2 (es) 2022-04-19

Family

ID=71575804

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017433A CO2021017433A2 (es) 2019-06-28 2021-12-20 Agonistas del receptor del péptido-1 similar al glucagón

Country Status (28)

Country Link
US (2) US11655242B2 (es)
EP (2) EP3989972B1 (es)
JP (1) JP7256300B2 (es)
KR (1) KR20220012924A (es)
CN (1) CN114008033A (es)
AU (1) AU2020309064B2 (es)
BR (1) BR112021023923A2 (es)
CA (1) CA3144055C (es)
CL (1) CL2021003419A1 (es)
CO (1) CO2021017433A2 (es)
CR (1) CR20210599A (es)
DK (1) DK3989972T3 (es)
DO (1) DOP2021000273A (es)
EC (1) ECSP21093576A (es)
FI (1) FI3989972T3 (es)
HR (1) HRP20231586T1 (es)
HU (1) HUE065080T2 (es)
IL (1) IL288479A (es)
JO (1) JOP20210337A1 (es)
LT (1) LT3989972T (es)
MX (1) MX2021015328A (es)
PE (1) PE20220590A1 (es)
PL (1) PL3989972T3 (es)
PT (1) PT3989972T (es)
RS (1) RS64940B1 (es)
SI (1) SI3989972T1 (es)
TW (1) TWI751585B (es)
WO (1) WO2020263695A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
AU2020369568B2 (en) * 2019-10-25 2024-03-21 Gilead Sciences, Inc. GLP-1R modulating compounds
US20230051318A1 (en) 2019-12-02 2023-02-16 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
EP4097099A4 (en) 2020-02-07 2023-09-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
WO2021160127A1 (en) * 2020-02-13 2021-08-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN115279750A (zh) * 2020-03-18 2022-11-01 株式会社Lg化学 Glp-1受体激动剂、包含该激动剂的药物组合物及其制备方法
IL296336A (en) * 2020-03-18 2022-11-01 Lg Chemical Ltd A agonist for the glp-1 receptor, a pharmaceutical preparation containing it and a method for its preparation
CA3190163A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022042691A1 (en) 2020-08-28 2022-03-03 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CN115461334A (zh) * 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
JP2024514259A (ja) * 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法
CR20230495A (es) 2021-04-21 2023-11-30 Gilead Sciences Inc Compuestos moduladores del glp-ir carboxibenzimidazólicos.
BR112023022836A2 (pt) * 2021-05-03 2024-01-16 Carmot Therapeutics Inc Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
TW202310838A (zh) 2021-05-20 2023-03-16 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2023038039A1 (ja) 2021-09-08 2023-03-16 塩野義製薬株式会社 抗肥満作用の関与する疾患の予防及び治療用医薬
AU2022358915A1 (en) 2021-10-05 2024-05-09 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023169436A1 (zh) * 2022-03-08 2023-09-14 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024041609A1 (zh) * 2022-08-24 2024-02-29 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120053180A1 (en) * 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2018098781A1 (en) * 2016-12-01 2018-06-07 Eli Lilly And Company Pyrrolidinone compounds
DK3555064T5 (da) * 2016-12-16 2023-05-01 Pfizer GLP-1 receptoragonister og anvendelser deraf
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
BR112020024956A2 (pt) 2018-06-15 2021-03-09 Pfizer Inc. Agonistas de receptor de glp-1 e usos dos mesmos
EP3883928A4 (en) 2018-11-22 2022-06-29 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CR20210562A (es) * 2019-04-12 2022-02-18 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
AU2020369568B2 (en) * 2019-10-25 2024-03-21 Gilead Sciences, Inc. GLP-1R modulating compounds
CN114728939B (zh) 2019-11-15 2023-12-08 日东制药株式会社 Glp-1受体激动剂及其用途
US20230051318A1 (en) 2019-12-02 2023-02-16 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
CN115335374A (zh) 2020-01-29 2022-11-11 吉利德科学公司 Glp-1r调节化合物
WO2021160127A1 (en) 2020-02-13 2021-08-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
IL296336A (en) 2020-03-18 2022-11-01 Lg Chemical Ltd A agonist for the glp-1 receptor, a pharmaceutical preparation containing it and a method for its preparation
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
US20230295154A1 (en) 2020-04-29 2023-09-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Also Published As

Publication number Publication date
KR20220012924A (ko) 2022-02-04
DOP2021000273A (es) 2022-03-15
PL3989972T3 (pl) 2024-03-25
JP2022540044A (ja) 2022-09-14
TW202115040A (zh) 2021-04-16
RS64940B1 (sr) 2024-01-31
JP7256300B2 (ja) 2023-04-11
AU2020309064A1 (en) 2022-01-27
DK3989972T3 (da) 2023-12-04
SI3989972T1 (sl) 2024-01-31
US20200407347A1 (en) 2020-12-31
AU2020309064B2 (en) 2023-08-17
HUE065080T2 (hu) 2024-04-28
EP3989972A1 (en) 2022-05-04
EP3989972B1 (en) 2023-11-08
CA3144055C (en) 2024-01-02
TWI751585B (zh) 2022-01-01
BR112021023923A2 (pt) 2022-01-25
CR20210599A (es) 2021-12-22
JOP20210337A1 (ar) 2023-01-30
IL288479A (en) 2022-01-01
FI3989972T3 (fi) 2024-01-24
PT3989972T (pt) 2023-12-04
US11655242B2 (en) 2023-05-23
CN114008033A (zh) 2022-02-01
WO2020263695A1 (en) 2020-12-30
CL2021003419A1 (es) 2022-09-23
LT3989972T (lt) 2023-12-27
MX2021015328A (es) 2022-01-18
EP4302826A3 (en) 2024-04-17
PE20220590A1 (es) 2022-04-22
EP4302826A2 (en) 2024-01-10
HRP20231586T1 (hr) 2024-03-15
CA3144055A1 (en) 2020-12-30
ECSP21093576A (es) 2022-01-31
US20230250092A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
CO2021000453A2 (es) Compuestos coagonistas de gip/glp1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
DOP2017000153A (es) Compuestos co-agonistas de gip y glp-1
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
PE20220938A1 (es) Compuestos agonistas de gipr
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
EA201592281A1 (ru) Новые модуляторы рецептора glp-1
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
EA202191379A1 (ru) Комбинированное лечение nafld и nash
MX2021005725A (es) Tratamiento de la obesidad y sus complicaciones.
CL2021003342A1 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
CO2021002768A2 (es) Compuestos de 2,6-diaminopiridina
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
AR119173A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
AR125905A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
CL2017003143A1 (es) Composición multi-péptido.
CO2021018031A2 (es) Una composición farmacéutica para la diabetes mellitus
BR112021026790A2 (pt) Composto de pirimidina-5-carboxamida
ECSP23095307A (es) Agonista del receptor de glp-1 y composición y uso del mismo